THOUSAND OAKS, Calif., March 13, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA ® ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic ...

Please provide your email address to receive an email when new articles are posted on . Fewer clinical deterioration events were reported in patients receiving ravulizumab (9.3%) vs. placebo (16.9%).

Myasthenia gravis is a chronic autoimmune disorder that disrupts nerve-to-muscle signaling, causing weakness. Modern treatments help many people live typical life spans and enter remission.

Findings showed gefurulimab statistically significantly improved MG-ADL total score at week 26 compared with placebo. Topline data were announced from a phase 3 trial evaluating gefurulimab in adults ...

(RTTNews) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive for anti-acetylcholine ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) ...

Add Yahoo as a preferred source to see more of our stories on Google. Johnson & Johnson won U.S. approval on April 30, 2025, of its new drug Imaavy for generalized myasthenia gravis. (Courtesy of ...

(RTTNews) - The U.S. Food and Drug Administration has granted approval for argenx BV's Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis or gMG in adults who test positive for ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated ...